Post-Marketing Studies Document Extra VTE Risk for Baricitinib

(MedPage Today) -- LONDON--Baricitinib (Olumiant) failed to show noninferiority to tumor necrosis factor (TNF) inhibitors for venous thromboembolism (VTE) risk in FDA-required postmarketing studies, a researcher reported here.
In two large...